Lipocine reported a third-quarter net loss and provided updates on its postpartum-depression drug candidate, other neuroactive-steroid programs and international sales opportunities for TLANDO. Its central clinical milestone is a new Phase 3 study of BRLIZIO for postpartum depression, which the company says is needed to support a potential U.S. drug application.
Key details
- BRLIZIO for postpartum depression: Lipocine began the BLOOM study in September. The placebo-controlled outpatient Phase 3 trial is expected to enroll about 120 people with postpartum depression and is designed to provide efficacy and safety evidence for a potential application through the FDA’s 505(b)(2) pathway.
- FDA feedback: The agency indicated that Lipocine’s application package appears complete apart from the need for one positive, well-controlled Phase 3 trial. The company said FDA feedback and lessons from an earlier Phase 3 trial informed BLOOM’s design.
- Potential partnership: Lipocine continues to seek partners to develop, obtain approval for and commercialize BRLIZIO.
- Other neuroactive-steroid candidates: For LPCN 2201, an oral brexanolone program for major depressive disorder, Lipocine plans to submit a Phase 2 study protocol to the FDA after assessing its formulations. A study may follow, depending on resource priorities. For LPCN 2203, being developed for essential tremor, the company has completed oral pharmacokinetic studies and plans to submit a protocol for a proof-of-concept Phase 2 study. Further work on that program is also subject to resource priorities.
- TLANDO approvals and planned launches: Health Canada approved TLANDO, an oral testosterone treatment, in September for adult men with conditions associated with low or absent endogenous testosterone. Lipocine’s North American partner, Verity Pharma, is planning a Canadian launch in early 2027.
- UAE market: In July, distribution partner Pharmalink received marketing authorization in the United Arab Emirates for TESTYRA, the local name for TLANDO. Pharmalink is planning an early-2027 launch.
- Further international partnering: Lipocine continues to seek partners for TLANDO in territories outside the United States, Canada, South Korea, the Gulf Cooperation Council countries and Brazil.
- Cash and quarterly loss: Lipocine had $21.5 million in unrestricted cash, cash equivalents and marketable investment securities at September 30, up from $14.9 million at the end of 2025. As of November 4, the company reported approximately $28.5 million, unaudited. For the third quarter, it reported a net loss of $0.7 million, or $0.08 per diluted share.
Plain-English implications
BRLIZIO’s potential path to a U.S. application depends on a successful, well-controlled Phase 3 trial; the FDA’s feedback does not remove that requirement. TLANDO’s Canadian and UAE approvals add markets where launch plans are being handled by partners, while development of Lipocine’s other clinical candidates remains subject to the company’s resource priorities.